DTC ad oversight by FDA should include corrective ad campaigns, consumer rep suggests.
This article was originally published in The Tan Sheet
Executive Summary
DTC AD OVERSIGHT OF CORRECTIVE CAMPAIGNS SUGGESTED BY CONSUMER REP on the basis that FDA's current program does not ensure patients receive balanced information if a campaign is found to be misleading, National Women's Health Network Exec Director Cynthia Pearson told an agency "stakeholders" meeting Aug. 17. "If the FDA directs companies to revise an ad campaign or orders the ad pulled, consumers have no way of knowing that. An entire nation of magazine readers and TV viewers have seen the ad and the damage has already been done," Pearson asserted.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning